GL Ventures Research
Investment Thesis
GL Ventures (高瓴创投) is the dedicated early-stage venture capital platform of Hillhouse, spun out as an independent fund brand in February 2020 by Hillhouse founder and chairman Zhang Lei (Lei Zhang). It operates alongside Hillhouse's broader multi-stage platform (public equities, private equity/buyout, and real assets, presented at hillhouseinvestment.com), applying Hillhouse's long-term, fundamentals-driven research process to early-stage company selection. Under founding partner Li Liang (Luke Li), GL Ventures pursues a "co-creation" (共创) investment model: rather than passive capital, the fund embeds a deep value-creation team that helps portfolio companies with supply-chain introductions, talent, ESG tooling, and follow-on financing connections. The stated philosophy is to back disruptive technology innovation early and support it through incubation-style engagement into growth stages.
Sector Focus
GL Ventures' primary focus is hard technology, which accounted for roughly 70% of its investment activity in the first half of 2026: semiconductors, embodied AI and humanoid robotics, quantum computing, and energy storage/new energy hardware. It maintains a significant secondary focus on healthcare and biopharmaceuticals (innovative drugs, medical devices, diagnostics) and a smaller but continued consumer technology practice (D2C beauty, F&B, consumer electronics, sleep tech). Representative hard-tech bets include Horizon Robotics, Zilliz, Guoyi Quantum, and a dense cluster of 2025-2026 embodied-AI and robotics deals (Tashi Zhihang, Digua Robotics, Critical Point, Tianji Intelligent, Quanzhibo, Wujie Power, MoSense, LatentVerse, Liqing Intelligent). Healthcare bets include Clover Biopharmaceutical, MicroPort Medical Robot, Peijia Medical, Zhaoke Ophthalmology, Starna Therapeutics, and Xinkanghe Biopharmaceutical. Consumer names include Perfect Diary, Heytea, Monster Charging (Energy Monster), and Snapmaker.
Stage Focus
GL Ventures invests across the early-to-growth continuum: angel and seed rounds account for roughly 30% of first-half-2026 deal count, while Pre-A, Series A, and Series B rounds together make up over 40%. It is willing to write both the first institutional check (e.g., exclusive angel investor in Honghuo Intelligent) and large growth-stage follow-ons (e.g., continued participation through Digua Robotics' $120M Series B1).
Check Size
Check sizes vary widely with round type, from tens-of-millions-of-yuan angel checks up to nine-figure-dollar lead positions in headline rounds (co-lead of Tashi Zhihang's $455M Pre-A, the largest single-round financing in Chinese embodied-AI history). Precise per-check figures are not disclosed on the corporate site; the estimate below reflects the observed range with moderate confidence.
Lead Tendency
GL Ventures both leads and co-invests. It has led or co-led several 2025-2026 rounds outright (Nakai Quantum's first round, SportVision's Angel+ round, Xinkanghe Biopharmaceutical's Series round with North S&T Innovation Fund, Tianji Intelligent's Series B/B+ with Meituan, Tashi Zhihang's record Pre-A with HongShan) while frequently joining larger syndicates as a existing-shareholder follow-on investor (Digua Robotics, Wujie Power, Guanglian Xinke, ISHO, Vbot Vitapower).
Recent Activity
GL Ventures has been extremely active through 2025-2026: over 641 cumulative investments since inception, with roughly 60 completed in the first half of 2026 alone (26 in AI/robotics, 12 in consumer technology, 8 in semiconductors). In September 2025, GL Ventures and China's state-owned Pudong Venture Capital launched a CNY 280M (~$40M) AI-focused fund. Fund status is actively deploying, with no signs of slowdown.
Portfolio Highlights
Three portfolio companies — Sigenergy (Sige New Energy), Qunhe Technology (Kujiale), and Changguang Chenxin — listed on the Hong Kong Stock Exchange within a single week (April 16-17, 2026); GL Ventures' combined book equity value across the three exceeded HKD 27 billion at first-day pricing. GL Ventures is Sigenergy's largest external shareholder (14.89% stake). Other notable exits/IPOs include Monster Charging (Nasdaq: EM), Peijia Medical, Zhaoke Ophthalmology, and Tainuo Maibo (STAR Market). Critical Point, a dexterous-hand robotics spin-out of AgiBot, reached unicorn status within five months of founding with GL Ventures backing.
Team
- Zhang Lei (Lei Zhang), Founder & Chairman — Founded Hillhouse in 2005 with seed capital from the Yale University endowment; launched GL Ventures as Hillhouse's independent early-stage venture brand in 2020.
- Li Liang (Luke Li), Founding Partner, GL Ventures — Leads GL Ventures' manufacturing and hard-technology investing; a frequent public speaker on China's "advanced manufacturing" investment thesis and the fund's co-creation post-investment model; signed GL Ventures' strategic partnership with Hong Kong PolyU.
Decision Process
GL Ventures operates as a partnership under Li Liang with sector-focused investment leads; Hillhouse's broader deep-value-creation (DVC) team supports portfolio companies post-investment across supply chain, talent, and ESG.
Founder Preferences
GL Ventures gravitates toward founders with deep technical or scientific pedigrees — university spin-outs (Peking University quantum computing team behind Nakai Quantum, Tsinghua-founded LatentVerse, HKUST-founded MoSense) and operators with prior large-company or research-institute experience (e.g., Honghuo Intelligent's founder from exoskeleton robotics R&D; Oula Wanxiang's founder, formerly "Employee No. 1" of Huawei's Embodied Intelligence Lab).
Geographic Focus
GL Ventures invests overwhelmingly in mainland China (Beijing, Shanghai, Shenzhen, Hefei, Wuxi, Zhuhai), reflecting Hillhouse's Chinese origins, with selective international deals surfacing opportunistically (e.g., a 2026 lead investment in London-based Heywa Labs). The broader Hillhouse platform maintains offices spanning Hong Kong, Singapore, and London.